rs2602899 — ADH5 ADH5 Promoter NF-kB Variant

Regulatory SNP in the ADH5 promoter at a potential NF-kB binding site; the protective T allele reduces GSNOR expression, preserving the bronchodilator S-nitrosoglutathione and lowering childhood asthma risk

See your personal result for ADH5

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

ADH5 Promoter — The Enzyme That Depletes the Airway's Own Bronchodilator

Your airways produce a natural bronchodilator called S-nitrosoglutathione (GSNO)11 S-nitrosoglutathione (GSNO)
A molecule formed when nitric oxide binds to glutathione; GSNO relaxes airway smooth muscle and suppresses mast cell activation, functioning as an endogenous bronchodilator that is measurably depleted in asthmatic airways. The enzyme that breaks GSNO down is GSNOR22 GSNOR
S-nitrosoglutathione reductase, also known as ADH5 (Alcohol Dehydrogenase 5), encoded on chromosome 4; it catalyzes the NAD⁺-dependent reduction of GSNO to oxidized glutathione plus ammonia, effectively removing the bronchodilator from the airway milieu. The rs2602899 variant sits in the ADH5 gene's promoter at a potential binding site for NF-kB33 NF-kB
Nuclear factor kappa-light-chain-enhancer of activated B cells, a transcription factor that can drive ADH5 expression when airway inflammation is present. Your allele at this position determines how much GSNOR your airway tissue can produce in response to inflammatory signals — and therefore how much of your natural bronchodilator survives.

The Mechanism

The ADH5 gene is regulated in part by NF-kB, a master inflammation transcription factor. The rs2602899 C allele (the common reference allele) preserves this NF-kB binding site, allowing normal NF-kB-driven upregulation of GSNOR during airway inflammation. More GSNOR means faster GSNO catabolism: the natural bronchodilator is consumed more rapidly precisely when the airway is inflamed and needs it most.

The T allele (minor, ~31% globally) disrupts this potential NF-kB binding site, reducing GSNOR transcription. Lower GSNOR activity means GSNO accumulates to higher levels, maintaining bronchodilation and suppressing mast cell degranulation even under inflammatory conditions. Wu et al. 200744 Wu et al. 2007
Genetic variation in S-nitrosoglutathione reductase (GSNOR) and childhood asthma. J Allergy Clin Immunol 2007;119(4):889-896 noted that rs2602899 (and the adjacent rs2851301) are in "virtually complete linkage disequilibrium (r²=0.99)" with rs1154404, and that "carrying the minor allele for these two promoter SNPs may result in the loss of the potential NF-kB binding site and therefore could reduce GSNOR production."

ADH5/GSNOR also plays a separate role in formaldehyde detoxification — it oxidizes the hydroxymethylglutathione adduct formed when formaldehyde reacts with glutathione, neutralizing this reactive aldehyde. Reduced GSNOR expression from the T allele may therefore modestly reduce the airway's capacity to clear environmental formaldehyde, though this trade-off appears clinically secondary to the beneficial GSNO-preserving effect.

The Evidence

The human genetic evidence comes from Wu et al. 200755 Wu et al. 2007
Case-parent triad design in 532 Mexican families with asthmatic children aged 4–17; 7 GSNOR SNPs genotyped; TDT-based log-linear model; atopy defined by skin prick testing against 24 aeroallergens. Their directly-genotyped proxy rs1154404 (r²=0.99 with rs2602899) showed: one T allele, RR 0.77 (95% CI 0.61–0.97, p=0.028); two T alleles, RR 0.66 (95% CI 0.44–0.99, p=0.046). This dose-response relationship is consistent with an additive protective model, with the T allele at rs2602899 as the likely causal variant at the NF-kB site.

The mechanistic foundation is established from mouse and human studies. Que et al. Science 200566 Que et al. Science 2005
GSNOR-knockout mice, ovalbumin-sensitized allergen model, n=8–12 per group; airway hyperresponsiveness measured by methacholine challenge showed that GSNOR-null mice were protected from airway hyperresponsiveness despite having equivalent eosinophilic inflammation to wild-type mice — proving that GSNO specifically controls airway smooth muscle tone, not inflammatory infiltration. Que et al. 200977 Que et al. 2009
36 asthmatics vs 34 healthy controls, bronchoalveolar lavage SNO quantification, spirometry, methacholine PC20 confirmed the human relevance: asthmatic airways have lower SNO content and higher GSNOR activity, with GSNOR activity inversely correlated with methacholine PC20 (i.e., higher GSNOR → lower PC20 → worse airway hyperresponsiveness).

The evidence for rs2602899's specific functional effect on NF-kB-driven transcription has not been confirmed in independent reporter assays, making this an moderate evidence association rather than strong — the genetic epidemiology is replicated but the promoter functional claim remains mechanistically inferred.

Practical Actions

The CC genotype (common, ~48% globally) represents the baseline population susceptibility with an intact NF-kB binding site driving normal ADH5/GSNOR expression. CT and TT carriers have progressively reduced NF-kB-driven GSNOR expression and correspondingly better GSNO preservation.

For CC carriers with asthma, the practical implication is that their airway is at typical (not reduced) risk for GSNO depletion during inflammation. Strategies that reduce NF-kB-driven GSNOR induction or supplement the airway's nitric oxide signaling capacity are most relevant.

Interactions

rs2602899 sits adjacent to rs2851301 (position 99088976, one base upstream) — both are in near- complete LD (r²=0.99) with the directly-studied rs1154404, forming a three-SNP promoter haplotype block. The risk-increasing variant rs28730619 (RR 1.60 for GG homozygotes in Wu et al.) is a separate GSNOR SNP operating independently of the rs2602899 promoter block, and compound effects have not been formally studied.

GSNOR genotype has been shown to interact with ADRB2 (beta-2 adrenergic receptor) variants in determining bronchodilator response to albuterol — a separate pharmacogenomic consideration for asthmatic patients on beta-agonist therapy.

Genotype Interpretations

What each possible genotype means for this variant.

CC Intact NF-kB Site Normal

Common ADH5 promoter genotype — typical GSNOR expression and baseline asthma susceptibility

The C allele at rs2602899 preserves the potential NF-kB binding site in the ADH5 promoter. During airway inflammation, NF-kB activity can upregulate GSNOR transcription, increasing GSNO catabolism at a time when the airway most needs its endogenous bronchodilator. CC homozygotes carry this inflammatory induction capacity on both chromosomes. The protective T allele (absent here) would reduce NF-kB-driven GSNOR upregulation, allowing GSNO to accumulate. With CC, asthma risk at this locus is at population baseline — the Wu et al. 2007 study showed no elevated risk above baseline for CC genotypes, only a reduced risk for T allele carriers.

CT One Protective Allele Beneficial

One T allele — moderately reduced GSNOR expression and modestly lower asthma risk

Heterozygous CT carriers have one intact and one disrupted NF-kB binding site in the ADH5 promoter. This intermediate dosage corresponds to a dose-response protective effect: CT carriers show RR 0.77 and TT carriers RR 0.66 for asthma compared to CC homozygotes (Wu et al. 2007, PMID 17543375). The additive model suggests each T allele incrementally preserves GSNO by reducing the NF-kB-driven upregulation of GSNOR during inflammation. The T allele frequency is ~45% in Europeans, ~13% in East Asians, ~51% in South Asians, and ~11% in Latinos, making CT the most common genotype in European populations.

TT Both Protective Alleles Beneficial

Two T alleles — maximum reduction in GSNOR expression at this site, lowest asthma risk from this variant

TT homozygotes have the T allele on both chromosomes, disrupting both copies of the potential NF-kB binding site in the ADH5 promoter. Wu et al. 2007 (PMID 17543375) showed a consistent dose-response: CC → RR 1.0 (reference), CT → RR 0.77, TT → RR 0.66, consistent with a purely additive protective model. The mechanism is reduced NF-kB-driven GSNOR transcription during airway inflammation, preserving GSNO as an endogenous bronchodilator and suppressing mast cell degranulation. The clinical implication is the greatest genetically-conferred protection at this locus against asthma susceptibility. Note that this protection is specifically at the GSNOR regulation level; other pathway variants remain independently relevant.

A secondary consideration: with lower GSNOR activity, TT carriers may have modestly reduced formaldehyde detoxification capacity since ADH5 handles the hydroxymethylglutathione intermediate formed when formaldehyde binds glutathione. This is unlikely to be clinically significant at normal environmental exposures but may warrant attention in occupationally exposed individuals.